IDEAS home Printed from https://ideas.repec.org/p/oec/elsaad/115-en.html
   My bibliography  Save this paper

Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward

Author

Listed:
  • Martin Wenzl

    (OECD)

  • Suzannah Chapman

    (OECD)

Abstract

This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines.

Suggested Citation

  • Martin Wenzl & Suzannah Chapman, 2019. "Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward," OECD Health Working Papers 115, OECD Publishing.
    • Handle: RePEc:oec:elsaad:115-en
    DOI: 10.1787/6e5e4c0f-en
    as

    Download full text from publisher

    File URL: https://doi.org/10.1787/6e5e4c0f-en
    Download Restriction: no
    File URL: https://libkey.io/10.1787/6e5e4c0f-en?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Hofmarcher, Thomas & Ericson, Oskar & Lindgren, Peter, 2022. "Cancer in Ireland – Disease Burden, Costs and Access to Medicines," IHE Report / IHE Rapport 2022:4, IHE - The Swedish Institute for Health Economics.
    2. Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca, 2023. "Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service," PharmacoEconomics, Springer, vol. 41(1), pages 107-117, January.
    3. Karen M. Facey & Jaime Espin & Emma Kent & Angèl Link & Elena Nicod & Aisling O’Leary & Entela Xoxi & Inneke Vijver & Anna Zaremba & Tatyana Benisheva & Andrius Vagoras & Sheela Upadhyaya, 2021. "Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel," PharmacoEconomics, Springer, vol. 39(9), pages 1021-1044, September.
    4. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
    5. Jae Ho Jung & Dae Jung Kim & Kangho Suh & Jaeeun You & Je Ho Lee & Kyung In Joung & Dong Churl Suh, 2021. "International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    6. Natalie Bohm & Sarah Bermingham & Frank Grimsey Jones & Daniela C. Gonçalves-Bradley & Alex Diamantopoulos & Jessica R. Burton & Hamish Laing, 2022. "The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe," PharmacoEconomics, Springer, vol. 40(1), pages 13-29, January.
    7. Russo, Pierluigi & Carletto, Angelica & Németh, Gergely & Habl, Claudia, 2021. "Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey," Health Policy, Elsevier, vol. 125(9), pages 1140-1145.
    8. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.

    More about this item

    JEL classification:

    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I13 - Health, Education, and Welfare - - Health - - - Health Insurance, Public and Private
    • O32 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Management of Technological Innovation and R&D
    • O38 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Government Policy

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oec:elsaad:115-en. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/eloecfr.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.